Popoola Victor O, Keebler Daniel, Skornicki Michelle, Sobel Rachel E, Lucia Jackie, Breskin Alexander, Askin Gulce, Asubonteng Julius, Patrone Clarke, Shao Ping, Szendrey Andrew, Kong Amanda
Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA
Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.
BMJ Open. 2025 Jun 26;15(6):e098311. doi: 10.1136/bmjopen-2024-098311.
Background rates are critical for contextualising safety signals arising from COVID-19-related interventions in investigational or real-world settings.
To estimate background rates of medical events of interest (MEI) for which COVID-19 infection and/or COVID-19 interventions may be risk factors in two US claims databases.
DESIGN, SETTING AND PARTICIPANTS: This retrospective cohort study spans the pre-COVID-19 (2018-2019) and COVID-19 (2020-2021) periods. We constructed three cohorts, in each of Inovalon/HealthVerity (Inovalon/HV) and Optum databases: a COVID-19-positive adult cohort (2020-2021), a paediatric cohort (2018-2021) and a high-risk cohort (2018-2021) comprising patients at increased risk for severe COVID-19. Participants were indexed on the day they first qualified to enter each cohort during the study period. Background rates of 17 MEI were estimated per 1000 person-years (PY) with 95% CIs.
Annual incidence rates (IRs) of 17 MEI.
Overall, 758 414 (COVID-19-positive adults; 57.8% women), 12 513 664 (high-risk adults; 56.8% women) and 8 510 627 (paediatric patients; 49.1% women) patients were identified in the HV database. IRs of MEI varied substantially by year, data source, study cohort and duration of follow-up. The IRs of MEI were highest among COVID-19-positive adults and lowest among paediatric patients. For example, IR of myocarditis/pericarditis per 1000 PY was 3.0 (95% CI: 2.6 to 3.4) in the COVID-19-positive adult cohort vs 0.36 (95% CI: 0.34 to 0.37) among high-risk adults and 0.05 (95% CI: 0.05 to 0.06) among paediatric patients. In the COVID-19-positive adult cohort, we observed higher IRs during 90-day follow-up (eg, IR of acute myocardial infarction (AMI) 26.5 (95% CI: 25.3 to 27.7)) vs 365-day follow-up (eg, IR of AMI 20.0 (95% CI: 9.2 to 20.8)) and during 2020 compared with 2021. IRs were higher in the high-risk adult and paediatric populations during the pre-COVID-19 period than during the COVID-19 pandemic.
Substantial variability was observed in IRs of MEI by study cohort, year, data source and follow-up duration. When generating background rates for contextualising safety signals from COVID-19 interventions, careful consideration must be given to the indicated subpopulation of interest, COVID-19-related temporal variations and data sources.
背景发生率对于在研究或现实环境中阐释与2019冠状病毒病(COVID-19)相关干预措施产生的安全信号至关重要。
在美国的两个理赔数据库中估计19种感兴趣的医疗事件(MEI)的背景发生率,对于这些事件,COVID-19感染和/或COVID-19干预措施可能是风险因素。
设计、设置和参与者:这项回顾性队列研究涵盖COVID-19之前(2018 - 2019年)和COVID-19期间(2020 - 2021年)。我们在Inovalon/HealthVerity(Inovalon/HV)和Optum数据库中各构建了三个队列:一个COVID-19阳性成人队列(2020 - 2021年)、一个儿科队列(2018 - 2021年)和一个高危队列(2018 - 2021年),高危队列由COVID-19重症风险增加的患者组成。参与者在研究期间首次符合进入每个队列的资格之日被编入索引。每1000人年(PY)估计了17种MEI的背景发生率及95%置信区间(CI)。
17种MEI的年发病率(IR)。
总体而言,在HV数据库中识别出758414例(COVID-19阳性成人;57.8%为女性)、12513664例(高危成人;56.8%为女性)和8510627例(儿科患者;49.1%为女性)患者。MEI的发病率因年份、数据来源、研究队列和随访时间而有很大差异。MEI的发病率在COVID-19阳性成人中最高,在儿科患者中最低。例如,每1000 PY的心肌炎/心包炎发病率在COVID-19阳性成人队列中为3.0(95% CI:2.6至3.4),在高危成人中为0.36(95% CI:0.34至0.37),在儿科患者中为0.05(95% CI:0.05至0.06)。在COVID-19阳性成人队列中,我们观察到90天随访期间的发病率较高(例如,急性心肌梗死(AMI)的发病率为26.5(95% CI:25.3至27.7)),而365天随访期间(例如,AMI的发病率为20.0(95% CI:9.2至20.8))以及2020年相较于2021年发病率更高。在COVID-19之前的时期,高危成人和儿科人群的发病率高于COVID-19大流行期间。
观察到MEI的发病率在研究队列、年份、数据来源和随访时间方面存在很大差异。在为阐释COVID-19干预措施的安全信号生成背景发生率时,必须仔细考虑所指定的感兴趣亚人群、与COVID-19相关的时间变化以及数据来源。